As of November 01, 2008

All diagnostic tests in our pipeline are based on our proprietary DNA methylation technology and biomarkers and address a combined cancer molecular diagnostics market with a potential of several billion USD. Beyond our lead program in colorectal cancer screening, our cancer screening programs in prostate and lung cancer offer attractive product and partnering opportunities.

Our screening tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma or urine. They rely on the sensitive detection of tumor DNA shed into the blood stream, urine or other body fluids the tumors are exposed to. This DNA differs little from DNA of healthy tissue in its sequence but has a cancer-specific DNA methylation pattern in certain genes. Epigenomics’ sensitive assay technologies detect these patterns in specific genes and thus require only DNA fragments shed from very few cells of the tumor into body fluids as a diagnostic biomarker.